Amgen Withdraws EU Application For Its Infliximab Biosimilar

In a change of strategy, Amgen has withdrawn its European application for biosimilar infliximab.

Compass_Strategy
A change in product strategy motivates Amgen to withdraw its application for marketing authorization • Source: Shutterstock

More from Strategy

More from Business